Your patient has anxiety, and you’ve tried the usual medications. You’ve rotated through your favorite SSRIs and SNRIs, tried some of the benzodiazepines, and even given buspirone a whirl to no avail. It’s time to go off-label.
Read More
Most treatment guidelines recommend cognitive behavioral therapy as first-line psychotherapy for anxiety disorders. In this article, Dr. Glen Spielmans will give you a brief primer of CBT techniques for panic disorder, social phobia, and obsessive-compulsive disorder, as well as review whether, for these conditions, CBT is indeed superior to other forms of therapy.
Read More
Abilify (aripiprazole), which has long been FDA-approved for both schizophrenia and manic episodes of bipolar disorder, was recently approved for augmentation of antidepressants in patients with treatment-resistant depression.
Read More
Clinical trials show which treatments work for “the average patient,” but we have little ability to predict which treatment will work best for any individual patient. QEEG (quantitative EEG) is a method in which a computer program reads EEG tracings and scores them along certain dimensions.
Read More
Anecdotally, adding an atypical antipsychotic to an antidepressant is a common practice for achieving a response in patients who have failed several medication trials. Do the data support this use of atypical antipsychotics?
Read More
To begin with, Dr. Friedman, I’d like to start with the diagnosis of PTSD. Given that patients sometimes come to us for disability evaluations and therefore have a secondary gain for getting the PTSD diagnosis, do you have any good tips for how we can be sure that we are making the proper diagnosis?
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
